Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Bio-Rad Laboratories ( (BIO) ) is now available.
Bio-Rad Laboratories has provided an update regarding its investment in Sartorius AG, which disclosed its financial results for the year ending December 31, 2024, on February 17, 2025. Sartorius AG reported sales revenue of €3,380.7 million, a gross profit of €1,524.4 million, and a net profit of €137.4 million, reflecting its financial performance and operational insights.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. operates in the life sciences and clinical diagnostics industry, providing products and services for research and clinical laboratories.
YTD Price Performance: -12.43%
Average Trading Volume: 201,146
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.02B
For detailed information about BIO stock, go to TipRanks’ Stock Analysis page.